{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:19:06Z","timestamp":1770466746880,"version":"3.49.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Health Labour Sciences Research","award":["22KC1005"],"award-info":[{"award-number":["22KC1005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Benzodiazepines (BZDs) activate the \u03b3-aminobutyric acid (GABA) subtype A (GABAA) receptors, and thus are widely used medicines for the treatment of anxiety and insomnia. For chronic use, tolerance to BZDs is a major problem. Patients with chronic insomnia that develop tolerance to BZDs lose therapeutic effects but also potentially suffer from BZD dependence resulting in BZD withdrawal. The development of such treatments is important for the appropriate use of BZDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Research articles regarding investigation of BZD dependence were searched on PubMed, Embase, and Scopus databases using keywords \u201cbenzodiazepine\u201d, \u201cdependence\u201d, \u201ctreatment\u201d.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>When BZDs are taken chronically, continuous GABAA binding results in up-regulation of \u03b1-amino-3-hydroxy-5-methyl-4-lisoxazolepropionic acid (AMPA) glutamate receptor function and release of brain-derived neurotrophic factor (BDNF). Released BDNF binds to its specific receptor tropomyosin-related kinase receptor B (TrkB). Enhanced BDNF-TrkB signaling activates protein phosphatase 2A (PP2A). Activated PP2A dephosphorylates GABAA receptors, resulting in the downregulation of the GABAA receptor function. Reduced GABAA receptor function augments long-term potentiation (LTP), AMPA-mediated glutamatergic neuroplasticity, by reducing LTP inhibition by GABAA receptor function. Augmented LTP enhances extreme anxiety, which leads to BZD dependence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Therefore, iInhibiting dephosphorylation of the GABAA receptor by PP2A, PP2A inhibitors could reduce LTP and anxiety, restoring BZD effectiveness and resulting in possible therapeutic effects for BZD dependence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgae136","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T18:45:48Z","timestamp":1731696348000},"page":"335-340","source":"Crossref","is-referenced-by-count":3,"title":["Protein phosphatase 2A inhibitors: a possible pharmacotherapy for benzodiazepine dependence"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6813-3473","authenticated-orcid":false,"given":"Chisa","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University , Kobe 650-8530 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8951-7871","authenticated-orcid":false,"given":"Nobue","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University , Kobe 650-8530 ,","place":["Japan"]},{"name":"Department of Pharmacology, School of Medicine, Hyogo Medical University , Nishinomiya, Hyogo 663-8501 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6473-9808","authenticated-orcid":false,"given":"Masanori","family":"Nakai","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University , Kobe 650-8530 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-4063","authenticated-orcid":false,"given":"F Scott","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo , Toledo, OH 43614 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-7948","authenticated-orcid":false,"given":"Kazuo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima 890-8544 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-5107","authenticated-orcid":false,"given":"Kento","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima 890-8544 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-396X","authenticated-orcid":false,"given":"Tomoaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kagoshima University Graduate School of Medical and Dental Sciences , Kagoshima 890-8544 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5632-2426","authenticated-orcid":false,"given":"George R","family":"Uhl","sequence":"additional","affiliation":[{"name":"Neurology, VA Maryland Healthcare System , Baltimore, Maryland 21201 ,","place":["United States"]},{"name":"Departments of Neurology and Pharmacology, University of Maryland School of Medicine , Baltimore, Maryland 21201 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-8508","authenticated-orcid":false,"given":"Junichi","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Addiction and Experimental Therapeutics, Department of Pharmacy, School of Pharmacy, Hyogo Medical University , Kobe 650-8530 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"2025030500394723400_CIT0001","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00002826-198205030-00004","article-title":"Pharmacology of GABA","volume":"5","author":"Meldrum","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"2025030500394723400_CIT0002","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1096\/fasebj.4.5.2155149","article-title":"Molecular biology of GABAA receptors","volume":"4","author":"Olsen","year":"1990","journal-title":"FASEB J"},{"key":"2025030500394723400_CIT0003","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/08830738030180012101","article-title":"Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system","volume":"18","author":"Simeone","year":"2003","journal-title":"J Child Neurol"},{"key":"2025030500394723400_CIT0004","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pharmthera.2006.03.006","article-title":"Molecular diversity, trafficking and subcellular localization of GABAB receptors","volume":"110","author":"Bettler","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2025030500394723400_CIT0005","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","article-title":"Hooked on benzodiazepines: GABAA receptor subtypes and addiction","volume":"34","author":"Tan","year":"2011","journal-title":"Trends Neurosci"},{"key":"2025030500394723400_CIT0006","first-page":"6","article-title":"Mechanisms of sleep induction by GABA(A) receptor agonists","volume":"68","author":"Harrison","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2025030500394723400_CIT0007","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2174\/1381612054021024","article-title":"GABA(A) receptor channel pharmacology","volume":"11","author":"Johnston","year":"2005","journal-title":"Curr Pharm Des"},{"key":"2025030500394723400_CIT0008","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, dangers, and clinical considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol Int"},{"key":"2025030500394723400_CIT0009","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/brainsci12040419","article-title":"Keeping the balance: GABA(B) receptors in the developing brain and beyond","volume":"12","author":"Bassetti","year":"2022","journal-title":"Brain Sci"},{"key":"2025030500394723400_CIT0010","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABA(A) receptor: positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"2025030500394723400_CIT0011","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"M\u00f6hler","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"2025030500394723400_CIT0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0899-5885(18)30256-9","article-title":"comprehensive review of sedative and analgesic agents","volume":"9","author":"Shields","year":"1997","journal-title":"Crit Care Nurs Clin North Am"},{"key":"2025030500394723400_CIT0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/157488612805076624","article-title":"Long-term benzodiazepine use and mortality: are we doing the right studies","volume":"7","author":"Amarasuriya","year":"2012","journal-title":"Curr Drug Saf"},{"key":"2025030500394723400_CIT0014","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-981-32-9705-0_20","article-title":"Role of benzodiazepines in anxiety disorders","volume":"1191","author":"Balon","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2025030500394723400_CIT0015","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10072-022-06397-x","article-title":"Clonazepam for the management of sleep disorders","volume":"44","author":"Raggi","year":"2023","journal-title":"Neurol Sci"},{"key":"2025030500394723400_CIT0016","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.22nr03385","article-title":"Update on managing insomnia in primary care: insights from an expert consensus group","volume":"25","author":"Rosenberg","year":"20232023","journal-title":"Prim Care Companion CNS Disord"},{"key":"2025030500394723400_CIT0017","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/jcm12041629","article-title":"Long-term use of insomnia medications: an appraisal of the current clinical and scientific evidence","volume":"12","author":"Zee","year":"2023","journal-title":"J Clin Med"},{"key":"2025030500394723400_CIT0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0031-6997(25)00468-5","article-title":"Benzodiazepines: use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacol Rev"},{"key":"2025030500394723400_CIT0019","doi-asserted-by":"publisher","first-page":"244","DOI":"10.9740\/mhc.2023.10.244","article-title":"Efficacy and safety of pharmacotherapy in chronic insomnia: a review of clinical guidelines and case reports","volume":"13","author":"Del Rio Verduzco","year":"2023","journal-title":"Ment Health Clin"},{"key":"2025030500394723400_CIT0020","doi-asserted-by":"publisher","first-page":"1212028","DOI":"10.3389\/fpsyt.2023.1212028","article-title":"Long-term use of benzodiazepines in chronic insomnia: a European perspective","volume":"14","author":"Soyka","year":"2023","journal-title":"Front Psychiatry"},{"key":"2025030500394723400_CIT0021","doi-asserted-by":"publisher","first-page":"416864","DOI":"10.1155\/2012\/416864","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators","volume":"2012","author":"Vinkers","year":"2012","journal-title":"Adv Pharmacol Sci"},{"key":"2025030500394723400_CIT0022","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/DSS.0000000000003407","article-title":"Safety and efficacy of oral benzodiazepines for periprocedural anxiolysis: a systematic review","volume":"48","author":"Boettler","year":"2022","journal-title":"Dermatol Surg"},{"key":"2025030500394723400_CIT0023","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1381612023396681","article-title":"Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal","volume":"8","author":"Bateson","year":"2002","journal-title":"Curr Pharm Des"},{"key":"2025030500394723400_CIT0024","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence","volume":"38","author":"Brett","year":"2015","journal-title":"Aust Prescr"},{"key":"2025030500394723400_CIT0025","first-page":"90","article-title":"Side effects of treatment with benzodiazepines","volume":"22","author":"Uzun","year":"2010","journal-title":"Psychiatr Danub"},{"key":"2025030500394723400_CIT0026","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced","volume":"77","author":"Lader","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025030500394723400_CIT0027","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMc1705239","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N Engl J Med"},{"key":"2025030500394723400_CIT0028","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.phrs.2015.12.030","article-title":"Activation-induced regulation of GABAA receptors: Is there a link with the molecular basis of benzodiazepine tolerance","volume":"109","author":"Gravielle","year":"2016","journal-title":"Pharmacol Res"},{"key":"2025030500394723400_CIT0029","doi-asserted-by":"publisher","first-page":"172996","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABA(A) receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"2025030500394723400_CIT0030","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","article-title":"Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats","volume":"85","author":"Di Chiara","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025030500394723400_CIT0031","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/syn.10271","article-title":"Dopamine responsiveness to drugs of abuse: a shell-core investigation in the nucleus accumbens of the mouse","volume":"50","author":"Zocchi","year":"2003","journal-title":"Synapse"},{"key":"2025030500394723400_CIT0032","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1002\/jcph.1918","article-title":"Pharmacology of drugs used as stimulants","volume":"61","author":"Docherty","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2025030500394723400_CIT0033","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/164_2019_251","article-title":"Molecular mechanisms of amphetamines","volume":"258","author":"Reith","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"2025030500394723400_CIT0034","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0306-4522(03)00476-7","article-title":"Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity","volume":"122","author":"Guilarte","year":"2003","journal-title":"Neuroscience"},{"key":"2025030500394723400_CIT0035","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","article-title":"Opioids excite dopamine neurons by hyperpolarization of local interneurons","volume":"12","author":"Johnson","year":"1992","journal-title":"J Neurosci"},{"key":"2025030500394723400_CIT0036","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"key":"2025030500394723400_CIT0037","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF02801973","article-title":"Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration","volume":"106","author":"Finlay","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"2025030500394723400_CIT0038","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0014-2999(94)90301-8","article-title":"Opposite effects of midazolam and beta-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis","volume":"261","author":"Murai","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"2025030500394723400_CIT0039","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/acschemneuro.6b00358","article-title":"Diazepam inhibits electrically evoked and tonic dopamine release in the nucleus accumbens and reverses the effect of amphetamine","volume":"8","author":"Gomez","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"2025030500394723400_CIT0040","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0014-2999(87)90072-0","article-title":"Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity","volume":"142","author":"O\u2019Brien","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"2025030500394723400_CIT0041","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1021\/acschemneuro.8b00268","article-title":"Local GABAA receptor-mediated suppression of dopamine release within the nucleus accumbens","volume":"10","author":"Brodnik","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"2025030500394723400_CIT0042","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1124\/jpet.117.241802","article-title":"Diazepam concurrently increases the frequency and decreases the amplitude of transient dopamine release events in the nucleus accumbens","volume":"364","author":"Schelp","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"2025030500394723400_CIT0043","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0924-977x(00)00137-1","article-title":"Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam","volume":"11","author":"Bentu\u00e9-Ferrer","year":"2001","journal-title":"Eur neuropsychopharmacol"},{"key":"2025030500394723400_CIT0044","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol Rev"},{"key":"2025030500394723400_CIT0045","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1101\/lm.042192.116","article-title":"Effects of drugs of abuse on hippocampal plasticity and hippocampus-dependent learning and memory: contributions to development and maintenance of addiction","volume":"23","author":"Kutlu","year":"2016","journal-title":"Learn Mem"},{"key":"2025030500394723400_CIT0046","doi-asserted-by":"publisher","first-page":"105572","DOI":"10.1016\/j.neuint.2023.105572","article-title":"Addictive drugs modify neurogenesis, synaptogenesis and synaptic plasticity to impair memory formation through neurotransmitter imbalances and signaling dysfunction","volume":"169","author":"Rezayof","year":"2023","journal-title":"Neurochem Int"},{"key":"2025030500394723400_CIT0047","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1124\/jpet.107.121798","article-title":"Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in Hippocampal CA1 neurons","volume":"322","author":"Song","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"2025030500394723400_CIT0048","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cne.21866","article-title":"Increased AMPA receptor GluR1 subunit incorporation in rat hippocampal CA1 synapses during benzodiazepine withdrawal","volume":"511","author":"Das","year":"2008","journal-title":"J Comp Neurol"},{"key":"2025030500394723400_CIT0049","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s11033-022-08110-9","article-title":"Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model","volume":"50","author":"Warlick","year":"2023","journal-title":"Mol Biol Rep"},{"key":"2025030500394723400_CIT0050","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/sj.npp.1300531","article-title":"Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety","volume":"29","author":"Van Sickle","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"2025030500394723400_CIT0051","doi-asserted-by":"publisher","first-page":"1010107","DOI":"10.3389\/fncel.2022.1010107","article-title":"Role of hippocampal circKcnk9 in visceral hypersensitivity and anxiety comorbidity of irritable bowel syndrome","volume":"16","author":"Liu","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"2025030500394723400_CIT0052","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pediatrneurol.2021.01.011","article-title":"Brain-derived neurotrophic factor in neonatal seizures","volume":"118","author":"Sullivan","year":"2021","journal-title":"Pediatr Neurol"},{"key":"2025030500394723400_CIT0053","doi-asserted-by":"publisher","first-page":"122282","DOI":"10.1016\/j.lfs.2023.122282","article-title":"TrkB\/BDNF signaling pathway and its small molecular agonists in CNS injury","volume":"336","author":"Wang","year":"2024","journal-title":"Life Sci"},{"key":"2025030500394723400_CIT0054","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-3-642-45106-5_9","article-title":"BDNF and synaptic plasticity, cognitive function, and dysfunction","volume":"220","author":"Lu","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"2025030500394723400_CIT0055","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1515\/revneuro-2015-0072","article-title":"Molecular mechanism linking BDNF\/TrkB signaling with the NMDA receptor in memory: the role of Girdin in the CNS","volume":"27","author":"Itoh","year":"2016","journal-title":"Rev Neurosci"},{"key":"2025030500394723400_CIT0056","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.neuropharm.2013.06.024","article-title":"BDNF mechanisms in late LTP formation: a synthesis and breakdown","volume":"76 Pt C","author":"Panja","year":"2014","journal-title":"Neuropharmacology"},{"key":"2025030500394723400_CIT0057","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s0028-3908(98)00035-5","article-title":"A role for BDNF in the late-phase of hippocampal long-term potentiation","volume":"37","author":"Korte","year":"1998","journal-title":"Neuropharmacology"},{"key":"2025030500394723400_CIT0058","doi-asserted-by":"publisher","first-page":"10072","DOI":"10.1523\/JNEUROSCI.22-23-10072.2002","article-title":"Heterozygous knock-out mice for brain-derived neurotrophic factor show a pathway-specific impairment of long-term potentiation but normal critical period for monocular deprivation","volume":"22","author":"Bartoletti","year":"2002","journal-title":"J Neurosci"},{"key":"2025030500394723400_CIT0059","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/s0896-6273(00)80140-3","article-title":"Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice","volume":"16","author":"Patterson","year":"1996","journal-title":"Neuron"},{"key":"2025030500394723400_CIT0060","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/sj.npp.1300192","article-title":"Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice","volume":"28","author":"Hall","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"2025030500394723400_CIT0061","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.euroneuro.2014.11.004","article-title":"Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: responsiveness and tolerance to diazepam","volume":"25","author":"Leggio","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2025030500394723400_CIT0062","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.neuron.2010.08.012","article-title":"Elevated BDNF after cocaine withdrawal facilitates LTP in medial prefrontal cortex by suppressing GABA inhibition","volume":"67","author":"Lu","year":"2010","journal-title":"Neuron"},{"key":"2025030500394723400_CIT0063","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13041-017-0325-8","article-title":"Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model","volume":"10","author":"Olsen","year":"2017","journal-title":"Mol Brain"},{"key":"2025030500394723400_CIT0064","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1349-7006.2009.01438.x","article-title":"Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis","volume":"101","author":"Wada","year":"2010","journal-title":"Cancer Sci"},{"key":"2025030500394723400_CIT0065","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2174\/156800961131300093","article-title":"Protein phosphatase 2A as a potential target for treatment of adult T cell leukemia","volume":"13","author":"Mori","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"2025030500394723400_CIT0066","first-page":"587","article-title":"Rubratoxin B, a toxic metabolite of Penicillium rubrum","volume":"18","author":"Moss","year":"1968","journal-title":"Chem Ind"},{"key":"2025030500394723400_CIT0067","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/0014-4800(81)90039-3","article-title":"Rubratoxin B hepatotoxicity: an electron microscopic study","volume":"34","author":"Lockard","year":"1981","journal-title":"Exp Mol Pathol"},{"key":"2025030500394723400_CIT0068","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.canlet.2017.11.035","article-title":"LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation","volume":"415","author":"Ho","year":"2018","journal-title":"Cancer Lett"},{"key":"2025030500394723400_CIT0069","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-020-03517-5","article-title":"Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma","volume":"148","author":"Maggio","year":"2020","journal-title":"J Neurooncol"},{"key":"2025030500394723400_CIT0070","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","article-title":"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial","volume":"23","author":"Chung","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025030500394723400_CIT0071","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/WNR.0000000000001678","article-title":"LB100 attenuates methamphetamine-induced behavioral sensitization by inhibiting the Raf1-ERK 1\/2 cascade in the caudate putamen","volume":"32","author":"Shang","year":"2021","journal-title":"Neuroreport"},{"key":"2025030500394723400_CIT0072","doi-asserted-by":"publisher","first-page":"134817","DOI":"10.1016\/j.neulet.2020.134817","article-title":"The effect of protein phosphatase 2A inhibitor LB100 on regulating methamphetamine induced conditioned place preference in mice","volume":"721","author":"Qian","year":"2020","journal-title":"Neurosci Lett"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/3\/335\/60686572\/rgae136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/3\/335\/60686572\/rgae136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:40:01Z","timestamp":1741135201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/77\/3\/335\/7901252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":72,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgae136","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,15]]}}}